Cirurgia de Esôfago
Estudo randomizado | Efeito do canrelizumabe vs. placebo adicionado à quimioterapia na sobrevida e na sobrevida livre de progressão em pacientes com carcinoma esofágico de células escamosas avançado ou metastático.
17 Set, 2021 | 11:55hEffect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge – JAMA Oncology (gratuito por tempo limitado)
Comentário no Twitter
Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of camrelizumab to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival https://t.co/DAlhmtgvv1
— JAMA (@JAMA_current) September 14, 2021
Diretrizes SAGES para o tratamento cirúrgico do refluxo gastresofágico.
21 Jul, 2021 | 09:50hSAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD) – Surgical Endoscopy
Impacto global do câncer atribuído ao consumo de álcool – “Em termos globais, estima-se que 741.300 casos, ou 4,1% de todos os novos casos de câncer em 2020, foram atribuídos ao consumo de álcool.”
14 Jul, 2021 | 11:36hComunicado de imprensa: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet
Comentários: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian E Expert reaction to study of alcohol and cancer – Science Media Centre
Estudo randomizado | Eficácia de longo prazo da quimiorradioterapia neoadjuvante somada à cirurgia para o tratamento de carcinoma esofágico de células escamosas localmente avançado.
13 Jul, 2021 | 11:09h
Comentário no Twitter
Long-term outcomes from the NEOCRTEC5010 demonstrated the survival benefit of neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for patients with locally advanced esophageal squamous cell carcinoma https://t.co/UBBEEAynsy
— JAMA Surgery (@JAMASurgery) June 29, 2021
Ranitidina absolvida? Estudo do FDA mostra que a ranitidina não é convertida ao carcinógeno NDMA, independentemente da dieta.
12 Jul, 2021 | 11:23hEditorial: Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) Formation
Comentário: Ranitidine: FDA finds no evidence of elevated NDMA, regardless of diet
Comentário no Twitter
Despite ranitidine (zantac) being pulled from market last year, a new study from the FDA did not find evidence that it increases concentrations of the carcinogenic metabolite people were worried about (i.e., it's probably safe). From @JAMA_current https://t.co/AdRic2GdXS
— Zack Williams (@QuantPsychiatry) June 28, 2021
In this crossover, randomized clinical trial, oral ranitidine did not significantly increase 24-hour urinary excretion of NDMA when administered with a noncured-meats diet or a cured-meats diet. https://t.co/EszRvfJOFJ
— JAMA (@JAMA_current) June 28, 2021
Estudo randomizado: Quimioterapia de intensidade reduzida em pacientes idosos frágeis com câncer gastresofágico avançado propicia uma melhor experiência ao paciente, sem perda significativa no controle da doença.
20 Mai, 2021 | 10:42h
Comentário no Twitter
The GO2 trial tested reduced intensity of chemo for pts w adv gastroesophageal cancer & found reducing intensity led to comparable survival but w improved patient experience, & decision-making can be enhanced using geriatric assessment https://t.co/DtZOXcozo7 #GeriOnc
— JAMA Oncology (@JAMAOnc) May 13, 2021
Resultados de longo prazo em estudo randomizado confirmam os benefícios da quimiorradioterapia neoadjuvante somada à cirurgia para câncer esofágico.
20 Mai, 2021 | 10:41h
Comentários no Twitter
Out at @ASCO_pubs
🔟yr Outcome of Neoadj #Chemoradiotherapy➕Surgery for #EsophagealCancer☑️Show OS benefit in locally advanced resectable esophageal or junctional #Cancer who receive preop chemorad🧪☢️ According to CROSS, persists at least🔟years‼️https://t.co/yJSibSveAh pic.twitter.com/UssnzuFiEe
— Gil Morgan (@weoncologists) May 14, 2021
Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists – 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck pic.twitter.com/2JwV0iOvoB
— ASCO Publications (@ASCO_pubs) May 5, 2021
Estudo randomizado: Entre pacientes com câncer esofágico, anastomose intratorácica após esofagectomia total ou híbrida minimamente invasiva resultou em menores taxas de vazamento anastomótico e melhores desfechos quando comparada com anastomose cervical.
18 Mai, 2021 | 10:38hIntrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial – JAMA Surgery (gratuito por tempo limitado)
Comentário convidado: Does the Location Matter for the Anastomosis for Minimally Invasive Esophagectomy? (gratuito por tempo limitado)
Comentário no Twitter
Intrathoracic anastomosis after MIE is associated with a lower anastomotic leakage rate and better outcome for patients with mid to distal esophageal or gastro-esophageal junction cancer: results of the ICAN trial https://t.co/CXv2CeCnuX pic.twitter.com/QCYg4UJeyF
— JAMA Surgery (@JAMASurgery) May 12, 2021